What are the potential adverse effects of taking mineralocorticoid receptor antagonists (MRAs)?
The use of mineralocorticoid receptor antagonists (MRAs) may lead to a clinically important increase in the number of patients experiencing hyperkalaemia, as well as some evidence of worsening renal function and an increase in hypotension. There was also a clinically important increase in gynaecomastia in patients using spironolactone, though the very low quality evidence suggested that there was no clinically important difference between eplerenone and placebo group.